相关实验视频

Updated: Mar 13, 2026

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

克里佐替尼通过调节纤维细胞激活来减轻布莱米辛诱导的肺纤维化

Yujie Shi¹, Zhiyi Li¹, Ruxuan Chen¹

¹Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Journal of thoracic disease

|March 12, 2026

概括

抗癌药物crizotinib通过抑制纤维细胞激活和关键信号通路,在治疗肺纤维化方面表现有前途. 这项研究表明crizotinib作为一种潜在的新疗法用于异常性肺纤维化 (IPF).

科学领域:

肺部病理学肺部病理学
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

异形性肺纤维化 (IPF) 是一种慢性,渐进的肺部疾病.
克里佐替尼是一种氨酸激酶抑制剂 (TKI),用于非小细胞肺癌 (NSCLC).
像pSTAT3,pAKT和pERK这样的信号通路都涉及到IPF和NSCLC,这是crizotinib的目标.

研究的目的:

在肺纤维化模型中研究crizotinib的抗纤维化疗效.
探索crizotinib潜在抗纤维菌作用的潜在机制.

主要方法:

*体外*:在TGF-β1刺激和crizotinib治疗后,分析了纤维细胞激活和信号通路.
*体内*:用白素 (BLM) 诱导的肺纤维化小鼠模型来评估肺功能,纤维化和分子标记.
进行了西斑分析以验证信号通路抑制.

主要成果:

克里佐替尼在体外减少了纤维素,原蛋白1和α-平滑肌肉的活性表达,抑制了纤维细胞的激活和迁移.
在体内,crizotinib改善了BLM治疗小鼠的肺功能,减少了纤维化病变,并减少了纤维化因子.
克里佐替尼抑制了PI3K/AKT/mTOR,STAT3和ERK的信号通路.

结论:

克里佐替尼通过抑制纤维细胞的增殖和激活来缓解肺纤维化.
该药物有效地抑制了关键的纤维细胞信号通路,包括PI3K/AKT/mTOR,STAT3和ERK.
克里佐替尼为患有异常性肺纤维化 (IPF) 的患者提供了潜在的新疗法选择.

关键词:

克里佐丁尼布 (crizotinib) 是一种可以性淋巴瘤激酶抑制剂 (ALK 抑制剂)纤维细胞的细胞.肌纤维细胞激活激活肺部纤维化肺部纤维化

更多相关视频

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...